CellWell record HH-224585
National perspectives of barriers by insurance and pharmacy benefit managers in pediatric inflammatory bowel disease
Brad D Constant; Jeremy Adler; Benjamin D Gold; Jennifer Dotson; Jenifer R Lightdale; Frank Scott; Shehzad Saeed; Sandra Kim; Jonathan Moses; Edwin F de Zoeten; Lucia Mirea; Andrew Ritchey; Brad Pasternak
2025
In plain language
Pediatric IBD patients experiencing payor barriers faced median 18-day treatment delays; 60% suffered adverse outcomes or reduced quality of life, including 21% hospitalizations.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-224585
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.